[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621460":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":57,"collaborators":59,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Shanghai Longwood Biopharmaceuticals Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"LW402 100 mg, PO BID","EXPERIMENTAL",null,[13],"Drug: LW402",{"label":15,"type":10,"description":11,"interventionNames":16},"LW402 150 mg, PO BID",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"LW402 placebo tablets,PO.BID","PLACEBO_COMPARATOR",[21],"Drug: Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","LW402","LW402 tablets",[9,15],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Placebo","LW402 placebo tablets",[18],[33],{"name":34,"affiliation":35,"role":36},"Janzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"Barbara Chen","CONTACT","+86-21-63634910","barbara@lwbiopharma.com",[44],{"facility":35,"status":11,"city":45,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Beijing","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":56,"role":40,"phone":11,"phoneExt":11,"email":11},"Jianzhong Zhang",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[60],{"name":61,"class":6},"Tigermed Consulting Co., Ltd","100621460","phase-3-evaluation-of-the-efficacy-and-safety-of-oral-lw402-tablets-for-the-treatment-of-patients-with-moderate-to-severe-atopic-dermatitis-100621460",false,"NCT07370909","Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis","A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.","Inclusion Criteria:\n\n* Subjects voluntarily provided informed consent and agreed to participate in the study.\n* Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form).\n* At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening.\n* At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:\n\n  * Total AD lesion area ≥ 10% of body surface area (BSA)\n  * Investigator's Global Assessment (IGA) score ≥ 3\n  * Eczema Area and Severity Index (EASI) score ≥ 16\n\nExclusion Criteria:\n\n* Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors.\n* Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus \\[SLE\\], inflammatory bowel disease \\[IBD\\], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).","ALL","18 Years","75 Years",{"count":73,"type":74},480,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.",[80],"Moderate to Severe Atopic Dermatitis","NOT_YET_RECRUITING","2026-01-27",{"date":84,"type":85},"2026-01-29","ACTUAL",{"date":87,"type":74},"2026-01-30",{"date":89,"type":74},"2028-12-31",{"name":5,"class":6},1]